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In  mature  mammals  the  bone  marrow  is  the  major  site  of  development  of 
lymphohemopoietic cells, including precursors of T  and B  lymphocytes. Acute lym- 
phoblastie leukemia  (ALL) in humans is generally considered to be a  malignancy of 
lymphoid progenitor cells in bone marrow; a  minority of patients have malignancies 
with a thymic phenotype and only rare patients have a mature T  or B cell phenotype 
(1, 2). Cells from some ALL patients are known to have cytoplasmic immunoglobulin 
and to be of the pre-B phenotype  (3,  4). Cell surface structures  on ALL cells might 
provide  markers  for  lymphoid  progenitors.  Two  major  cell  surface  glycoproteins 
associated with ALL have been characterized: the HLA-DR or Ia-like antigens (5, 6) 
and a  100,000-mol wt structure (gpl00)  (7, 8). A monoclonal antibody (9)  against the 
gp 100/common ALL antigen structure has been reported (10). Monoclonal antibodies 
are also available that identify monomorphic determinants of HLA-DR (11, 12). Both 
the HLA-DR and gpl00 determinants can be demonstrated on terminal deoxynucle- 
otidyl  transferase  (TdT)-positive  lymphocytes  in  normal  bone  marrow,  which  are 
considered to be lymphocyte precursors (13). 
In  our  study  a  monoclonal  antibody  raised  against  a  pre-B  form  of ALL  is 
described.  This  antibody  precipitates  an  -24,000-mol  wt  polypeptide  (p24)  on  the 
surface of lymphoid  leukemia  cells;  the  polypeptide  is  detectable  on the  surface  of 
bone marrow lymphohemopoietic precursors and in most cases of non-T, non-B ALL. 
Materials  and Methods 
Cells  for Immunization and Testing.  Established human hemopoietic cell lines used in this study 
were obtained and grown as previously described (14). Fresh leukemic cells were obtained from 
samples submitted from multiple institutes for analysis at the University of Minnesota or the 
Imperial Cancer Research  Fund  (ICRF), London. Normal peripheral  blood  (PB)  and  bone 
marrow (BM) were obtained from volunteers. Heparinized PB and BM were generally separated 
using Ficoil-Hypaque (F-H) density sedimentation. Interface cells were washed and incubated 
at 37°C for at least  2 h to remove labile immunoglobulin before further study. 
Hybridoma Production, Cloning, and Screemng.  NALM-6-M1 cells  (15) were used for immuni- 
zation of BALB/c mice as previously described (16). The BALB/c myeloma cell line P3-NSI-1- 
Ag4-1 (NS-1) was used for fusion. Hybridomas of interest  were removed from the original fusion 
well and subcuhured onto BALB/c nonadherent spleen cell feeders in round-bottomed micro- 
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titer plates.  Supernates were  assayed for antibody reactivity against the  immunizing cells; 
subcultures with the highest titers were cloned by limiting-dilution (0.5 cells/well) as previously 
described (14, 16). A one-step complement-dependent cytotoxicity assay (16) was used to screen 
culture supernates. 
Immunofluorescence Assays.  Indirect immunofluorescenee was used to assess binding of mono- 
clonal antibody to cell populations. Monoclonal antibody or control ascitie fluid was mixed 
with  target cells and  incubated  for 30  min  at  4°C.  After washing, cells were stained with 
fluoreseein isothiocyanate (FITC) -goat anti-mouse Ig (GAMG). FITC-GAMG was from the 
ICRF, or from  Meloy Laboratories Inc., Springfield, Va. Antibodies were generally affinity 
purified  F(ab')2  fragments  and  were  absorbed  with  insolubilized human  Ig.  The  second 
incubation was continued for 30 min at 4°C, followed by washing, mounting, and examination 
with a  Zeiss fluorescent microscope equipped with Ploem epi-illumination (Carl Zeiss, Inc., 
New York). 
Double-Marker Analysis of Hemopoietic Cells.  Double-marker analysis was performed in BM to 
determine  the  relationship between  binding  of the  monoelonal  antibody  BA-2  and  other 
markers. Cells were first stained with BA-2 and FITC-GAMG and then with tetramethylrho- 
damine isothiocyanate (TRITC)  goat anti-human polyvalent Ig (N. L. Cappel Laboratories, 
Inc., Cochranviile, Pa.) for 30 min at 4°C or, incubated with sheep erythrocytes followed by 
centrifugation and incubation for 1 h at 4°C. In experiments to demonstrate phagocytosis, BM 
cells were mixed with latex particles and incubated at 37°C for 1 h and then stained with BA- 
2  and  FITC-GAMG as described above.  In some experiments cells were examined for the 
presence of nuclear TdT and the BA-2  + cells. Cells were first stained in suspension with BA-2 
antibody followed by FITC-GAMG, cytocentrifuged, fixed with cold methanol and incubated 
with rabbit anti-calf TdT, (kindly supplied by Dr. Fred Bollum, Uniformed University of the 
Health  Sciences, Bethesda,  Md.)  for  30  min.  Cells were  then  washed  and  incubated  with 
TRITC  goat  anti-rabbit antibody for  30  min,  washed,  mounted,  and  examined  using  the 
fluorescent microscope. 
Additional Antibodies Used in  This Study.  Monoclonal anti-HLA-DR monomorphic determi- 
nant  antibodies were  obtained  from  Dr.  Walter Bodmer,  London  and  Dr. John  Hansen, 
University of Washington, Seattle and termed DA-2 (11)  and 7.2  (12),  respectively. A mono- 
elonal antibody (J5) against gpl00/cALLa was kindly provided by Dr. Jerome Ritz and Dr. 
Stuart Schlossman, Sidney Farber Cancer Institute, Boston, Mass. (10). Heterologous absorbed 
(rabbit) anti-gpl00 and rabbit anti-HLA-DR were produced at the ICRF. 
Radiolabeling, Immune Complex Formation, and Sodium Dodecyl Sulfate (SDS)  Polyac(ylamide Gel 
Electrophoresis (PAGE).  Metabolic labeling of cells with  [SSS]methionine as well as external 
labeling with a2aI using lactoperoxidase were conducted with standard methods as previously 
described  (8).  Immune  complexes  were  precipitated  using  Staphylococcus aureus Protein  A. 
Standard methods were utilized in SDS-PAGE which has been described previously in detail 
elsewhere (8). 
Results and  Discussion 
Hybridoma  Production.  Cells  from  the  pre-B  ALL-derived cell  line,  NALM-6-MI, 
were  used  tbr  mouse  immunizations.  NALM-6-M1  cells are  CyIgM  +,  SIg-,  HLA- 
DR +, gpl00/cALLa +, TdT +, T  lymphocyte antigen-, E  rosette- (15).  Mouse spleen 
cells were  fused  with  NS-1  cells and  colonies  that  appeared  in  culture  wells were 
screened  using NALM-6-M 1 and  the  autologous  Epstein-Barr  virus-transformed  B 
lymphoblastoid cell line, B85, allowing detection of antibodies recognizing leukemia- 
associated and/or progenitor antigens. Cells from a  NALM-6  + B85- fusion well were 
cloned  at  limiting-dilution and  passaged  in  pristane-primed  mice.  The  antibody 
product of one clone, BA-2, was shown to be a  Staphylococcus aureus protein A-binding 
IgG antibody. The titer of BA-2 ascites fluid in indirect immunofluoreseence was  1 : 
1,000. 
Immunochemical Characterization  of the Structure Recognized by BA-2.  NALM-1 cells (17) 728  KERSEY ET AL.  BRIEF  DEFINITIVE REPORT 
were labeled with 1251 using the lactoperoxidase method. Cell extracts were incubated 
with  BA-2, and  immunoprecipitation and  SDS-PAGE were carried  out.  Results of 
radioautographs using a  15% polyacrylamide gel are shown in Fig.  1. Lanes A-D are 
results  obtained  using increasing amounts of BA-2 antibody  (2-20 #1  of undiluted 
BA-2  ascitic  fluid).  A  strong  single  band  is  demonstrated  at  ~24,000  mol  wt, 
henceforth designated p24/BA-2. A similar band was observed when SIg  + CLL cells 
were  treated  in  a  similar  manner  (data  not  shown).  In  contrast  are  shown  results 
obtained with the rabbit heteroantiserum against gpl00 (lane E)  and the anti-gp 100 
monoclonal antibody J5 in lane F.  Lanes E and F show the expected single band at 
100,000  mol wt; the absence of a band in lane F serves as a control indicating that 
BALB/c mouse ascitic fluid does not contain antibody that precipitates a structure of 
24,000  mol wt.  Rabbit  HLA-DR antiserum  was  utilized  in  lane  G  and  shows  the 
expected  bimolecular  complex  at  -34,000  and  29,000  mol  wt.  Experiments  were 
performed using either  reducing or nonreducing conditions; similar  bands  in  both 
groups indicate that p24/BA-2 is a single chain polypeptide without internal disulfide 
bonds. The biosynthesis and shedding of p24/BA-2 by leukemia cells was also studied. 
NALM-1 cells  were biosynthetically labeled with  [35S]methionine. Cell extracts and 
culture supernates were subjected to immunoprecipitation and SDS-PAGE. The p24 
band was observed in both cell extracts and in cell supernates. These results provide 
direct evidence to indicate that p24/BA-2 is synthesized by the cells and not absorbed 
from the serum-containing tissue culture medium. 
Distribution of  p24/BA-2 on Normal Hemopoietic Cells.  Normal hemopoietic cells were 
studied  for the presence of p24/BA-2 positivity using indirect  immunofluorescence. 
As shown in Table I, erythrocytes and granulocytes do not demonstrate p24/BA-2 in 
indirect  immunofluorescence. Small  numbers of p24/BA-2  + cells  were found in  PB 
(mean of < 1%) and larger numbers in the mononuclear populations in BM (mean of 
3%). Analysis of p24/BA-2  + cells in blood and BM using phase-microscopy indicated 
that  these  cells  were  small,  round  mononuclear  cells  that  were  brightly  stained. 
Double-marker assays demonstrated that BA-2  + PB and BM cells from normal adults 
were  invariably  E  rosette-  (E-),  surface  Ig-  (SIg-),  and  nonphagocytic.  Double- 
marker assays in adult BM revealed that 40-60% (mean 50%) of the BM population 
positive for TdT was also p24/BA-2  +. These results are consistent with the hypothesis 
that  the lymphohemopoietic progenitor population in  human BM contains cells  of 
the TdT  ÷ p24/BA-2  ÷ phenotype. 
Flo.  1.  Immune  precipitation and SDS-PAGE  with BA-2,  anti-gpl00  and anti-HLA-DR  antibody. 
NALM-I cells were externally labeled with ~2Sl using the  lactoperoxidase method. Protein A- 
antibody-antigen complexes were denatured under reducing conditions and subjected to PAGE  on 
a 15% polyacrylamide  slab gel. In lanes A-D, BA-2  was used with increasing amounts of antibody, 
and in lanes E and F,(absorbed rabbit heteroantisera and mouse monoclonal  antibody, respectively) 
anti-gpl00 was used. Lane G shows results with rabbit anti-HLA-DR. KERSEY ET AL.  BRIEF  DEFINITIVE REPORT 
TABLE  I 
Distribution of p24 on Normal and Leukemic Lymphohemopoietic Cells 
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Results using indirect immunofluorescent mi- 
Cell type  croscopy and flow cytofluorimetry 
Normal lymphobemopoietic cells 
Erythrocytes 
Granulocytes 
PB Mononuclear cells (12 individuals tested) 
BM Mononuclear cells (11 individuals tested) 
Leukemic cells 
Non-T, non-B ALL (including pre-B ALL) (SIg- 
T  antigen-, E-, CylgM  ±) 
T  ALL (E  + and/or T  antigen  +) 
B CLL (Slg  +) 
Negative 
Negative 
Mean < 1% (range 0-2%) 
Mean 3% (range 2-5%)* 
54 Positive samples:~ (77%){} 
70 Total samples 
2 Positive samples 
71~  (18%)11 
5 Positive samples 
io~  (5o°1o)11 
* Cells were nonphagocytic, SIg-, E-, small to intermediate size, frequently TdT  +, lymphoid cells. 
* >10% positive cells. 
§ Staining when present was bright to moderate. 
H Staining when present was moderate to dim. 
Distribution ofp24/BA-2 on Leukemic Cells.  We evaluated the expression of p24/BA- 
2 on cells from patients with ALL. Results were obtained using indirect immunoflu- 
orescence microscopy and  in  many instances  confirmed using flow cytofluorimetry 
(FACS-I;  BD  FACS  Systems,  Mountain  View,  Calif.).  Samples  were  reported  as 
positive when > 10% of cells bound BA-2.70 cases of non-T, non-B, (including pre-B) 
common ALL were studied  (Table I).  54  of 70  (77%)  cases of non-T,  non-B  ALL 
bound  BA-2  antibody  in  indirect  immunofluoreseence.  Binding  of BA-2  in  non-T, 
non-B ALL as determined by intensity of fluorescence in the FACS and under the 
microscope, was moderate to bright.  In contrast  to results with  non-T, non-B ALL 
were results from patients with ALL of the T  phenotype (malignant cells were positive 
for E receptor or T  antigen[s]) in which only 2 out of 11  (18%) were positive, and both 
showed moderate to dim intensity of fluorescence. Cells from  10 patients with SIg  ÷ 
chronic lymphocytic leukemia  (CLL)  were studied  and  in  five eases  (50%)  binding 
was observed in  10-40% of cells; the binding was dim to moderate. No reactivity was 
observed in the other five cases of SIg  + CLL. 
Relationship  between p24/BA-2 and Other Surface Markers.  The relationship between 
p24/BA-2 and gpl00/cALLa was evaluated further in 64 patients with ALL. 34 of 64 
(53%) of cases of ALL had cells expressing both gp 100 and p24. Conversely, cells from 
15 of 64 (23%)  had no detectable p24 or gp 100. Discordance between the distribution 
of p24 and  gpl00 was evident  in  15  cases, 9  of which  were p24  +,  gpl00-  and 6  of 
which were p24-, gpl00  +.  HLA-DR and p24 were also compared; cells of 56 of 86 
cases  (65%)  of ALL were positive for both p24 and HLA-DR. Conversely,  13 of 86 
(15%)  were  negative  for  both  and  discordance  between  p24  and  HLA-DR  was 
observed in  17 cases (14 were HLA-DR  ÷, p24-, and 3 cases were p24  +, HLA-DR-). 
Although  p24/BA-2  appears to be restricted primarily to progenitor cells and most 
non-T leukemias within the lymphohemopoietic system, prelimary evidence indicates 
that some epithelial malignancies (e.g., carcinomas) and neuroectodermal malignan- 
cies (e.g., neuroblastoma) bear p24/BA-2 (data not shown). 
p24/BA-2  appears to differ from recently described  antigens  found primarily on 
human B lymphocytes. These determinants have tool wt of 54,000  (18), 65,000  (19) 730  KERSEY ET AL.  BRIEF  DEFINITIVE REPORT 
and  a  dimer of 40,000  and  150,000  (20).  We have produced  a  second  monoclonal 
antibody  after  immunization  with  NALM-6-M1.  This  antibody  (BA-I),  brightly 
stains  normal  and  malignant  SIg  ÷  lymphocytes,  including  chronic  lymphocytic 
leukemia (CLL); most cases of non-T, non-B ALL, and granulocytes but not normal 
or malignant T  lymphocytes (16).  Surface structures  found on T  lymphocytes were 
found  on  mature  lymphocytes and  have higher  molecular weights  than  p24/BA-2 
(21).  A 25,000-mol wt determinant may be the human homologue of Thy-1  (22); this 
determinant is found on all human thymocytes and peripheral T  cells. A  number of 
lymphocyte membrane antigen  groups including  TL, Lyt, Lyb, and Qa have been 
described in the mouse. All have a different tissue distribution and a higher molecular 
weight  (45,000-110,000)  than p24/BA-2 (reviewed 23). 
The  function  of p24/BA-2  on  the  surface of human  lymphohemopoieitc cells  is 
unknown. The demonstration of p24 + on TdT  + bone marrow cells suggests that p24 
is a normal gene product of cells contained within the lymphohemopoietic progenitor 
populations. The stable expression of p24/BA-2 on most non-T, non-B ALL may be 
a reflection of the level of maturation arrest present in these leukemic cells. 
Summary 
This study was directed at surface structures that are found on human lymphohe- 
mopoietic  progenitor  cells  in  normal  and  leukemic  bone  marrow.  A  monoclonal 
antibody was produced  against  an acute lymphoblastic leukemia  (ALL)  cell line of 
the  pre-B phenotype;  this  antibody  (BA-2)  was  used  to demonstrate a  cell  surface 
polypeptide of ~24,000  tool wt that  migrates similarly in  both reduced  and nonre- 
duced  form. This polypeptide, p24/BA-2, was shown by immune precipitation  and 
gel electrophoresis and  cell  distribution  studies  to be different  from HLA-DR and 
gpl00/cALLa, p24/BA-2 was present on the surface of 77% (54/70) of cases of non-T, 
non-B  ALL;  BA-2  staining  was  less  bright  or  nondetectable  in  surface  Ig  +  (SIg  +) 
chronic lymphocytic leukemia (CLL) and T  ALL and nondetectable on peripheral T 
and B lymphocytes. Approximately 3% of bone marrow mononuclear cells were p24/ 
BA-2  +, and these cells were E  rosette-, surface  (SIg-), and nonphagocytic.  Marrow 
TdT  +  progenitor cells  were  frequently  p24/BA-2  +.  Results  suggest  that  p24/BA-2 
represents a surface structure present on lymphohemopoietic bone marrow progenitor 
cells and that most common types of ALL bear the p24/BA-2 structure. 
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